Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test

被引:37
|
作者
Bernal, Samuel [1 ]
Palomares, Jose C. [1 ]
Artura, Antonio [2 ]
Parra, Manuel [1 ]
Cabezas, Jose L. [1 ]
Robles, Antonio [3 ]
Martin Mazuelos, Estrella [1 ]
机构
[1] Unit Infect Dis & Clin Microbiol UCEIM HU Valme, Seville, Spain
[2] HU Valme, Dept Gynecol & Obstet, Seville, Spain
[3] HU Valme, Dept Pathol, Seville, Spain
关键词
Papillomavirus; Urine; Cobas; 4800; Genotyping; DNA DETECTION; FOLLOW-UP; CANCER; PREVENTION; EFFICACY; WOMEN;
D O I
10.1016/j.jcv.2014.10.001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Human papillomavirus (HPV) is the main cause of cervical cancer. The development of non-invasive self-sample collection methods would have the potential advantage of increasing the acceptance of the screening procedures. Objectives: To compare human papillomavirus (HPV) DNA detection and genotyping with the Cobas 4800 HPV test (Roche Diagnostic, Spain) on paired cervical and first voided urine. Study design: Paired urine and cervical samples were collected from 125 women referred for evaluation of abnormal Pap smear results. Results: The overall percent agreement between HPV detection in urine and cervical samples was 88%. A substantial concordance rate of HPV DNA detection in both samples was observed (kappa = 0.76; 95% IC: 64-87). In this high prevalence population the sensitivity, specificity, NPV and PPV for detection of HPV DNA from urine versus cervical samples were 90.5% (95% IC: 80-95%), 85%, (95% IC: 74-92%), 89.8% (95% IC: 79.5-95.3) and 86.4% (95% IC: 76.1-92.7) respectively. Compared to histologically confirmed CIN 213 disease, the clinical sensitivity and specificity for the detection of high-risk HPV in urine samples were 95% (95% IC: 76-97%) and 52.4% (95% IC: 40-64%) respectively. Conclusions: These results suggest that urine samples processed with Cobas 4800 HPV test may be useful for clinical management of HPV infection. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:548 / 552
页数:5
相关论文
共 50 条
  • [41] Testing and Genotyping of High-Risk Human Papillomavirus by the cobas HPV Test and the Hybrid Capture 2 High-Risk HPV DNA Test Using Cervical and Vaginal Samples
    Pyne, Michael T.
    Law, Christian
    Hillyard, David R.
    Schlaberg, Robert
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (05) : 1720 - 1723
  • [42] Quality control of HPV test. Interlaboratory agreement of cobas 4800
    Alameda, F.
    Carrasco, M. A.
    Treserras, F.
    Muset, M.
    Bellosillo, B.
    Kopsteva, I.
    Lloveras, B.
    VIRCHOWS ARCHIV, 2017, 471 : S237 - S237
  • [43] Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population
    Liu, Stephanie S.
    Chan, Karen K. L.
    Wei, Tina N.
    Tse, Ka Yu
    Ngu, Siew F.
    Chu, Mandy M. Y.
    Lau, Lesley S. K.
    Cheung, Annie N. Y.
    Ngan, Hextan Y. S.
    PLOS ONE, 2022, 17 (08):
  • [44] A comparison of the MeltProA® HPV Test with the CobasA® HPV Test for detecting and genotyping 14 high-risk human papillomavirus types
    Tang, Zhiteng
    Xu, Ye
    Song, Najie
    Zou, Dongqing
    Liao, Yiqun
    Li, Qingge
    Pan, Chao
    ARCHIVES OF VIROLOGY, 2018, 163 (03) : 725 - 730
  • [45] Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial
    Darrel A. Cook
    Wendy Mei
    Laurie W. Smith
    Dirk J. van Niekerk
    Kathy Ceballos
    Eduardo L. Franco
    Andrew J. Coldman
    Gina S. Ogilvie
    Mel Krajden
    BMC Cancer, 15
  • [46] Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial
    Cook, Darrel A.
    Mei, Wendy
    Smith, Laurie W.
    van Niekerk, Dirk J.
    Ceballos, Kathy
    Franco, Eduardo L.
    Coldman, Andrew J.
    Ogilvie, Gina S.
    Krajden, Mel
    BMC CANCER, 2015, 15
  • [47] Comparison of DRY and WET vaginal swabs with cervical specimens in Roche Cobas 4800 HPV and Abbott RealTime High Risk HPV tests
    Jun, Jae Kwan
    Lim, Myong Cheol
    Hwang, Sang-Hyun
    Shin, Hye Young
    Hwang, Na Rae
    Kim, Yeon-Jin
    Yoo, Chong Woo
    Lee, Dong Ock
    Joo, Jungnam
    Park, Sang-Yoon
    Lee, Do-Hoon
    JOURNAL OF CLINICAL VIROLOGY, 2016, 79 : 80 - 84
  • [48] The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test
    Schiffman, Mark
    Boyle, Sean
    Raine-Bennett, Tina
    Katki, Hormuzd A.
    Gage, Julia C.
    Wentzensen, Nicolas
    Kornegay, Janet R.
    Apple, Raymond
    Aldrich, Carrie
    Erlich, Henry A.
    Tam, Thanh
    Befano, Brian
    Burk, Robert D.
    Castle, Philip E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (09) : 1304 - 1310
  • [49] Comparison of a Newly Developed HPV Genotyping Assay (Mojin HPV Kit) with Cobas 4800 HPV Test for Detection of High-Risk HPV in Specimens Collected in SurePath Solution
    Yang, Wan-Wei
    Wang, Zhi-Guo
    Chen, Guo-Fang
    Shi, Jian-Feng
    Chen, Juan
    Ma, Quan-Hui
    Zhou, Jing
    Mao, Xiao-Dong
    Liu, Chao
    Yao, Xiao-Ming
    CLINICAL LABORATORY, 2018, 64 (03) : 387 - 391
  • [50] Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
    Yang, Qing
    Du, Hui
    Qu, Xinfeng
    Dai, Wenkui
    Gui, Liming
    Li, Changzhong
    Wang, Chun
    Guo, Chunlei
    Zhang, Yi
    Wei, Lihui
    Belinson, J. L.
    Wu, Ruifang
    FRONTIERS IN PUBLIC HEALTH, 2022, 10